MX2017009505A - Derivados de 9h-pirrolo-dipiridina. - Google Patents

Derivados de 9h-pirrolo-dipiridina.

Info

Publication number
MX2017009505A
MX2017009505A MX2017009505A MX2017009505A MX2017009505A MX 2017009505 A MX2017009505 A MX 2017009505A MX 2017009505 A MX2017009505 A MX 2017009505A MX 2017009505 A MX2017009505 A MX 2017009505A MX 2017009505 A MX2017009505 A MX 2017009505A
Authority
MX
Mexico
Prior art keywords
pyrrolo
dipyridine
derivatives
dipyridine derivatives
radiopharmaceuticals
Prior art date
Application number
MX2017009505A
Other languages
English (en)
Other versions
MX378155B (es
Inventor
Anil Sabnis Yogesh
Mercier Joël
Provins Laurent
Vermeiren Céline
Original Assignee
Ucb Biopharma Sprl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ucb Biopharma Sprl filed Critical Ucb Biopharma Sprl
Publication of MX2017009505A publication Critical patent/MX2017009505A/es
Publication of MX378155B publication Critical patent/MX378155B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0455—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0459—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0463—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002—Heterocyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La invención se refiere a derivados de 9H-pirrolo-dipiridina de la fórmula I, procesos para prepararlos, composiciones farmacéuticas que los contienen y su uso como radiofármacos en particular como agentes de formación de imágenes para la detección de agregados Tau.
MX2017009505A 2015-02-02 2016-01-29 Derivados de 9h-pirrolo-dipiridina. MX378155B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP15153448 2015-02-02
PCT/EP2016/051993 WO2016124508A1 (en) 2015-02-02 2016-01-29 9h-pyrrolo-dipyridine derivatives

Publications (2)

Publication Number Publication Date
MX2017009505A true MX2017009505A (es) 2017-11-02
MX378155B MX378155B (es) 2025-03-10

Family

ID=52477553

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017009505A MX378155B (es) 2015-02-02 2016-01-29 Derivados de 9h-pirrolo-dipiridina.

Country Status (17)

Country Link
US (3) US20180022748A1 (es)
EP (1) EP3253762B1 (es)
JP (1) JP6579670B2 (es)
KR (1) KR102621513B1 (es)
CN (1) CN107207508B (es)
AU (1) AU2016214537B2 (es)
BR (1) BR112017016311A2 (es)
CA (1) CA2973648C (es)
CL (1) CL2017001923A1 (es)
DK (1) DK3253762T3 (es)
EA (1) EA036518B1 (es)
ES (1) ES2875734T3 (es)
IL (1) IL253381B (es)
MX (1) MX378155B (es)
MY (1) MY191590A (es)
SG (1) SG11201705727TA (es)
WO (1) WO2016124508A1 (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110046378A1 (en) 2008-02-14 2011-02-24 Siemens Medical Solutions Usa, Inc. Novel Imaging Agents for Detecting Neurological Dysfunction
US20180022748A1 (en) * 2015-02-02 2018-01-25 Ucb Biopharma Sprl 9h-pyrrolo-dipyridine derivatives
KR102472003B1 (ko) * 2016-07-22 2022-11-29 에이씨 이뮨 에스에이 타우 단백질 응집체를 이미징하기 위한 화합물
EP3487545A1 (en) 2016-07-22 2019-05-29 AC Immune S.A. Compounds for imaging tau protein aggregates
WO2018046428A1 (en) * 2016-09-09 2018-03-15 F. Hoffmann-La Roche Ag Process for preparation of 2-(6-nitropyridin-3-yl)-9h-dipyrido[2,3-b;3',4'-d]pyrrole
IL290809B2 (en) * 2016-11-01 2024-01-01 Arvinas Operations Inc Tau-protein targeting protacs and associated methods of use
CA3067455C (en) 2017-06-02 2021-11-23 Fujifilm Toyama Chemical Co., Ltd. Agent for preventing or treating spinocerebellar ataxia
JPWO2018221728A1 (ja) 2017-06-02 2020-04-02 富士フイルム富山化学株式会社 アルツハイマー型認知症予防または治療剤
BR112019024983A2 (pt) 2017-06-02 2020-06-23 Fujifilm Toyama Chemical Co., Ltd. Agente para reduzir a quantidade de proteína b amiloide
BR112019024878A2 (pt) * 2017-06-02 2020-06-16 Fujifilm Toyama Chemical Co., Ltd. Agente para prevenção ou tratamento de tauopatia
SG11201911512SA (en) 2017-06-02 2020-01-30 Fujifilm Toyama Chemical Co Ltd Agent for preventing or treating brain atrophy
WO2019088083A1 (ja) 2017-10-30 2019-05-09 富士フイルム富山化学株式会社 エモパミル結合タンパク質結合剤およびその利用
WO2019145291A1 (en) 2018-01-24 2019-08-01 Ac Immune Sa Gamma-carboline compounds for the detection of tau aggregates
WO2019145292A1 (en) * 2018-01-24 2019-08-01 Ac Immune Sa Azacarboline compounds for the detection of tau aggregates
KR20200113234A (ko) * 2018-01-24 2020-10-06 에이씨 이뮨 에스.에이. 이미징 화합물을 제조하는 신규한 방법
CN119954801A (zh) 2019-07-17 2025-05-09 阿尔维纳斯运营股份有限公司 Tau蛋白靶向化合物及相关使用方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1268771A (en) 1968-03-15 1972-03-29 Glaxo Lab Ltd Azacarbazoles
WO2008132454A1 (en) * 2007-04-26 2008-11-06 Ge Healthcare Limited Carbolines and their use as imaging agents
US20110046378A1 (en) * 2008-02-14 2011-02-24 Siemens Medical Solutions Usa, Inc. Novel Imaging Agents for Detecting Neurological Dysfunction
US8815840B2 (en) * 2008-12-19 2014-08-26 Bristol-Myers Squibb Company Carbazole and carboline kinase inhibitors
CN107011342A (zh) * 2012-05-22 2017-08-04 伊莱利利公司 用于检测神经功能障碍的基于咔啉和咔唑的成像剂
WO2014194169A1 (en) * 2013-05-31 2014-12-04 The General Hospital Corporation Radiosynthesis of tau radiopharmaceuticals
US9774356B2 (en) * 2013-07-24 2017-09-26 Telefonaktiebolaget Lm Ericsson (Publ) Method and apparatus relating to reception of radio signals
JP6194416B2 (ja) * 2013-10-08 2017-09-06 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ タウ−ｐｅｔリガンドとしてのジアザカルバゾール誘導体
WO2015110263A1 (en) * 2014-01-21 2015-07-30 Ac Immune Sa Carbazole and carboline compounds for use in the diagnosis, treatment, alleviation or prevention of disorders associated with amyloid or amyolid-like proteins
US20180022748A1 (en) * 2015-02-02 2018-01-25 Ucb Biopharma Sprl 9h-pyrrolo-dipyridine derivatives

Also Published As

Publication number Publication date
US11312716B2 (en) 2022-04-26
US20210047326A1 (en) 2021-02-18
US20180022748A1 (en) 2018-01-25
WO2016124508A1 (en) 2016-08-11
AU2016214537B2 (en) 2018-05-10
CA2973648C (en) 2023-09-26
JP2018503673A (ja) 2018-02-08
MY191590A (en) 2022-06-30
CL2017001923A1 (es) 2018-02-16
US12006316B2 (en) 2024-06-11
US20220213103A1 (en) 2022-07-07
CA2973648A1 (en) 2016-08-11
AU2016214537A1 (en) 2017-08-03
EP3253762A1 (en) 2017-12-13
EA201791733A1 (ru) 2018-01-31
KR20170113607A (ko) 2017-10-12
IL253381B (en) 2020-10-29
CN107207508A (zh) 2017-09-26
CN107207508B (zh) 2020-02-28
SG11201705727TA (en) 2017-08-30
KR102621513B1 (ko) 2024-01-04
EP3253762B1 (en) 2021-05-05
BR112017016311A2 (pt) 2018-03-27
MX378155B (es) 2025-03-10
ES2875734T3 (es) 2021-11-11
EA036518B1 (ru) 2020-11-18
DK3253762T3 (da) 2021-07-19
JP6579670B2 (ja) 2019-09-25
IL253381A0 (en) 2017-09-28

Similar Documents

Publication Publication Date Title
MX2017009505A (es) Derivados de 9h-pirrolo-dipiridina.
SV2017005587A (es) Nuevos derivados hidroxiester, un proceso para su preparacion y composiciones farmaceutacas que los contienen
SV2017005590A (es) Nuevos derivados hidroxiacido un proceso para su preparacion y composiciones farmaceuticas que los contienen
CO2018007443A2 (es) Nuevos derivados de amonio, un proceso para su preparación y composiciones farmacéuticas que los contienen
SV2018005791A (es) Nuevos derivados piperidinilo, un proceso para su preparación y composiciones farmacéuticas que los contienen
DOP2017000298A (es) Reguladores de nrf2
SV2017005588A (es) Nuevos derivados aminoacido, un proceso para su preparacion y composiciones farmaceuticas que los contienen
CL2014002093A1 (es) Compuestos derivados piperidinopirimidinicos; composicion farmaceutica que los comprende; uso en el tratamiento de infecciones viricas.
UY35467A (es) Compuestos orgánicos
NI201400079A (es) Nuevos derivados de pirrol, su procedimiento de preparación y las composiciones farmacéuticas que los contienen
SV2018005760A (es) Derivados de aminotiazol utiles como agentes antiviricos
GT201700023A (es) Derivados de heterociclico opcionalmente condensados de piridimina útiles para el tratamiento de enfermedades inflamatorias, metabolicas, oncológicas y autoinmunitarias
DOP2018000062A (es) Piridinona dicaboxamidas para uso como inhibidores de bromodominio
MX2017007377A (es) Compuestos organicos.
MX2018002416A (es) Derivados de 1,7-diaril-1,6-heptadien-3,5-diona, procedimiento para la preparación y uso de los mismos.
SV2018005657A (es) "nuevos derivados de imidazo[4,5-b]piridina, un proceso para su preparacion y composiciones farmaceuticas que los contienen"
MX2017000183A (es) Amidas de benzoxazinona como moduladores del receptor de mineralocorticoides.
CL2017000587A1 (es) Derivados de tetrahidroquinolina como inhibidores de bromodominio
DOP2018000066A (es) Compuestos útiles para inhibir ror-gamma-t
CL2014001862A1 (es) Compuestos derivados de morofolinilo sustituido, útiles como inhibidores de mogat-2; composicion farmaceutica que los comprende; uso en el tratamiento de hipertrigliceridemia.
CR20140051A (es) Compuestos de tiazol y oxazol de bencen-sulfonamida
UY35958A (es) Derivados de quinolina como insecticidas y acaricidas
ECSP17063489A (es) Derivados de nucleósidos sustituidos útiles como agentes antineoplásicos
SV2014004879A (es) Nuevos derivados tienopirimidina, un proceso para su preparación y composiciones farmacéuticas que los contienen
UY35999A (es) Indol- y bencimidazolcarboxamidas como insecticidas y acaricidas